NO2648726T3 - - Google Patents
Info
- Publication number
- NO2648726T3 NO2648726T3 NO11805292A NO11805292A NO2648726T3 NO 2648726 T3 NO2648726 T3 NO 2648726T3 NO 11805292 A NO11805292 A NO 11805292A NO 11805292 A NO11805292 A NO 11805292A NO 2648726 T3 NO2648726 T3 NO 2648726T3
- Authority
- NO
- Norway
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42059910P | 2010-12-07 | 2010-12-07 | |
| PCT/US2011/063817 WO2012078805A1 (en) | 2010-12-07 | 2011-12-07 | Polycyclic lpa1 antagonist and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO2648726T3 true NO2648726T3 (de) | 2018-09-01 |
Family
ID=45446189
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO11805292A NO2648726T3 (de) | 2010-12-07 | 2011-12-07 |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US9556133B2 (de) |
| EP (2) | EP2648726B1 (de) |
| JP (1) | JP6030567B2 (de) |
| KR (1) | KR101875246B1 (de) |
| CN (2) | CN103596566B (de) |
| AU (2) | AU2011338417B2 (de) |
| BR (1) | BR112013013950A2 (de) |
| CA (1) | CA2820884A1 (de) |
| CY (1) | CY1120342T1 (de) |
| DK (1) | DK2648726T3 (de) |
| EA (1) | EA024967B1 (de) |
| ES (1) | ES2674174T3 (de) |
| HR (1) | HRP20180970T1 (de) |
| HU (1) | HUE040397T2 (de) |
| IL (1) | IL226698B (de) |
| LT (1) | LT2648726T (de) |
| MX (1) | MX347544B (de) |
| NO (1) | NO2648726T3 (de) |
| PL (1) | PL2648726T3 (de) |
| PT (1) | PT2648726T (de) |
| RS (1) | RS57377B1 (de) |
| SG (1) | SG191041A1 (de) |
| SI (1) | SI2648726T1 (de) |
| SM (1) | SMT201800320T1 (de) |
| TR (1) | TR201809293T4 (de) |
| WO (1) | WO2012078805A1 (de) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201390821A1 (ru) | 2010-12-07 | 2013-10-30 | Амира Фармасьютикалс, Инк. | Антагонисты рецепторов лизофосфатидной кислоты и их применение |
| SG2014011555A (en) | 2011-08-15 | 2014-08-28 | Intermune Inc | Lysophosphatidic acid receptor antagonists |
| MX369801B (es) | 2012-12-28 | 2019-11-21 | Ube Industries | Compuesto heterociclico sustituido con halogeno. |
| TW201437200A (zh) * | 2013-01-15 | 2014-10-01 | Intermune Inc | 溶血磷脂酸受體拮抗劑 |
| CN105142635B (zh) | 2013-03-15 | 2021-07-27 | 艾匹根生物技术有限公司 | 有用于治疗疾病的杂环化合物 |
| CA2913634C (en) | 2013-06-07 | 2022-08-09 | The California Institute For Biomedical Research | Small molecule inhibitors of fibrosis |
| WO2015066456A1 (en) | 2013-10-31 | 2015-05-07 | Bristol-Myers Squibb Company | Radioligands for imaging the lpa-1 receptor |
| ES2732845T3 (es) * | 2013-12-04 | 2019-11-26 | Galmed Res & Development Ltd | Sales de Aramchol |
| GB201410741D0 (en) * | 2014-06-17 | 2014-07-30 | Babraham Inst And University Of Birmingham The | Novel diagnostic and therapeutic method |
| MX370408B (es) | 2014-06-27 | 2019-12-11 | Ube Industries | Sal de compuesto heterociclico sustituido con halogeno. |
| WO2016197009A1 (en) | 2015-06-05 | 2016-12-08 | Vertex Pharmaceuticals Incorporated | Triazoles for the treatment of demyelinating diseases |
| EP3378491A4 (de) * | 2015-11-20 | 2019-07-17 | UBE Industries, Ltd. | Pharmazeutische zusammensetzung zur behandlung und/oder prävention von nash |
| JP2018039755A (ja) * | 2016-09-08 | 2018-03-15 | 大塚化学株式会社 | ナトリウム２α−メチル−２β−（１，２，３−トリアゾール−１−イル）−メチルペナム−３α−カルボン酸１，１−ジオキシド一水和物結晶の製造方法 |
| JP2018039756A (ja) * | 2016-09-08 | 2018-03-15 | 大塚化学株式会社 | ナトリウム２α−メチル−２β−（１，２，３−トリアゾール−１−イル）−メチルペナム−３α−カルボン酸１，１−ジオキシド一水和物結晶の製造方法 |
| WO2018106643A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Heterocyclic azoles for the treatment of demyelinating diseases |
| WO2018106641A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Pyrazoles for the treatment of demyelinating diseases |
| WO2018106646A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Aminotriazoles for the treatment of demyelinating diseases |
| CN108318447B (zh) * | 2018-05-04 | 2020-12-18 | 山东大学 | 一种基于近红外光谱技术快速测定吡喹酮对映体组成的方法 |
| SI3802517T1 (sl) | 2018-06-07 | 2023-04-28 | Idorsia Pharmaceuticals Ltd | Alkoksi-substituirani piridinilni derivati kot antagonisti receptorja LPA1 in njihova uporaba pri zdravljenju fibroze |
| KR102224677B1 (ko) * | 2018-08-23 | 2021-03-08 | 가천대학교 산학협력단 | 티아졸로 피페라진 유도체 및 이를 유효성분으로 함유하는 자가면역질환 예방 또는 치료용 조성물 |
| JP7427658B2 (ja) | 2018-09-18 | 2024-02-05 | ブリストル－マイヤーズ スクイブ カンパニー | Ｌｐａアンタゴニストとしてのシクロペンチル酸 |
| US12428430B2 (en) | 2018-09-18 | 2025-09-30 | Bristol-Myers Squibb Company | Oxabicyclo acids as LPA antagonists |
| AR119162A1 (es) | 2019-06-18 | 2021-12-01 | Idorsia Pharmaceuticals Ltd | Derivados de piridin-3-ilo |
| JP7431961B2 (ja) | 2019-11-15 | 2024-02-15 | ギリアード サイエンシーズ， インコーポレイテッド | Ｌｐａ受容体アンタゴニストとしてのトリアゾールカルバメートピリジルスルホンアミド及びその使用 |
| JP7665619B2 (ja) | 2019-12-04 | 2025-04-21 | イドルシア・ファーマシューティカルズ・リミテッド | 線維性疾患の治療に使用するためのアゼチジンｌｐａ１受容体アンタゴニストのピルフェニドン及び／又はニンテダニブとの合剤 |
| KR102393079B1 (ko) | 2020-02-28 | 2022-04-29 | 한국화학연구원 | 가축 호흡기 질환의 예방 또는 치료용 조성물 |
| CN111608208B (zh) * | 2020-05-19 | 2022-01-11 | 浙江鲁班建材科技股份有限公司 | 一种时间可控制的吸水膨胀堵漏型预铺卷材 |
| TWI838626B (zh) | 2020-06-03 | 2024-04-11 | 美商基利科學股份有限公司 | Lpa受體拮抗劑及其用途 |
| CA3185689A1 (en) | 2020-06-03 | 2021-12-09 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| WO2022006470A1 (en) | 2020-07-01 | 2022-01-06 | Vanderbilt University | Methods of treatment for a kidney disease |
| JP2022115835A (ja) * | 2021-01-28 | 2022-08-09 | 大正製薬株式会社 | Ｌｐａ１受容体を拮抗するウレア化合物の結晶形及びそれらの製造方法 |
| CN117295717A (zh) | 2021-05-11 | 2023-12-26 | 吉利德科学公司 | Lpa受体拮抗剂及其用途 |
| JP7709612B2 (ja) | 2021-12-08 | 2025-07-16 | ギリアード サイエンシーズ， インコーポレイテッド | Ｌｐａ受容体アンタゴニスト及びそれらの使用 |
| KR102463504B1 (ko) | 2022-08-23 | 2022-11-04 | 주식회사 에네스지 | 원전 습분분리재열기의 종단온도차 보정 방법 |
| TW202432092A (zh) * | 2023-01-19 | 2024-08-16 | 大陸商江蘇恒瑞醫藥股份有限公司 | 三氮唑類化合物的可藥用鹽、晶型及其製備方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4229447A (en) | 1979-06-04 | 1980-10-21 | American Home Products Corporation | Intraoral methods of using benzodiazepines |
| US4596795A (en) | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
| US4755386A (en) | 1986-01-22 | 1988-07-05 | Schering Corporation | Buccal formulation |
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| US5739136A (en) | 1989-10-17 | 1998-04-14 | Ellinwood, Jr.; Everett H. | Intraoral dosing method of administering medicaments |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| TWI288136B (en) * | 2000-02-18 | 2007-10-11 | Kirin Brewery | Novel isoxazole and thiazole compounds and use thereof as drugs |
| US20030215462A1 (en) | 2001-12-21 | 2003-11-20 | Wacher Vincent J. | Use of UGT inhibitors to increase bioavailability |
| US20040014648A1 (en) | 2002-05-17 | 2004-01-22 | Faust Pharmaceuticals | Methods for the prevention and/or the treatment of neurological disorders |
| BRPI0410454A (pt) | 2003-05-19 | 2006-06-13 | Irm Llc | composições e compostos imunossupressores |
| WO2007016784A1 (en) | 2005-08-11 | 2007-02-15 | Merck Frosst Canada Ltd. | Novel substituted 1,2,3-tπazolylmethyl-benzothiophene or -indole and their use as leukotπene biosynthesis inhibitors |
| AR055041A1 (es) | 2005-03-23 | 2007-08-01 | Merck Frosst Canada Ltd | Tiadiazoles y oxadiazoles como inhibidores de la sintesis de leucotrienos. composiciones farmaceuticas. |
| US7405302B2 (en) | 2005-10-11 | 2008-07-29 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (FLAP) inhibitors |
| US7977359B2 (en) | 2005-11-04 | 2011-07-12 | Amira Pharmaceuticals, Inc. | 5-lipdxygenase-activating protein (FLAP) inhibitors |
| US20070225285A1 (en) | 2005-11-04 | 2007-09-27 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
| US20070219206A1 (en) | 2005-11-04 | 2007-09-20 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
| JP2009523820A (ja) | 2006-01-23 | 2009-06-25 | アミラ ファーマシューティカルス，インコーポレーテッド | ５−リポキシゲナーゼの三環系抑制剤 |
| GB2466121B (en) | 2008-12-15 | 2010-12-08 | Amira Pharmaceuticals Inc | Antagonists of lysophosphatidic acid receptors |
| GB2470833B (en) | 2009-06-03 | 2011-06-01 | Amira Pharmaceuticals Inc | Polycyclic antagonists of lysophosphatidic acid receptors |
-
2011
- 2011-12-07 MX MX2013006394A patent/MX347544B/es active IP Right Grant
- 2011-12-07 CN CN201180066933.5A patent/CN103596566B/zh not_active Expired - Fee Related
- 2011-12-07 AU AU2011338417A patent/AU2011338417B2/en not_active Ceased
- 2011-12-07 ES ES11805292.7T patent/ES2674174T3/es active Active
- 2011-12-07 KR KR1020137017670A patent/KR101875246B1/ko not_active Expired - Fee Related
- 2011-12-07 WO PCT/US2011/063817 patent/WO2012078805A1/en not_active Ceased
- 2011-12-07 LT LTEP11805292.7T patent/LT2648726T/lt unknown
- 2011-12-07 RS RS20180740A patent/RS57377B1/sr unknown
- 2011-12-07 JP JP2013543325A patent/JP6030567B2/ja not_active Expired - Fee Related
- 2011-12-07 HR HRP20180970TT patent/HRP20180970T1/hr unknown
- 2011-12-07 DK DK11805292.7T patent/DK2648726T3/da active
- 2011-12-07 SM SM20180320T patent/SMT201800320T1/it unknown
- 2011-12-07 CA CA2820884A patent/CA2820884A1/en not_active Abandoned
- 2011-12-07 TR TR2018/09293T patent/TR201809293T4/tr unknown
- 2011-12-07 US US13/992,022 patent/US9556133B2/en active Active
- 2011-12-07 BR BR112013013950A patent/BR112013013950A2/pt not_active IP Right Cessation
- 2011-12-07 PL PL11805292T patent/PL2648726T3/pl unknown
- 2011-12-07 EA EA201390840A patent/EA024967B1/ru not_active IP Right Cessation
- 2011-12-07 SG SG2013043740A patent/SG191041A1/en unknown
- 2011-12-07 CN CN201710849870.XA patent/CN107721940A/zh active Pending
- 2011-12-07 EP EP11805292.7A patent/EP2648726B1/de active Active
- 2011-12-07 NO NO11805292A patent/NO2648726T3/no unknown
- 2011-12-07 SI SI201131465T patent/SI2648726T1/en unknown
- 2011-12-07 HU HUE11805292A patent/HUE040397T2/hu unknown
- 2011-12-07 EP EP18163527.7A patent/EP3360552A1/de not_active Withdrawn
- 2011-12-07 PT PT118052927T patent/PT2648726T/pt unknown
-
2013
- 2013-06-02 IL IL226698A patent/IL226698B/en not_active IP Right Cessation
-
2016
- 2016-10-05 AU AU2016238848A patent/AU2016238848B2/en not_active Ceased
- 2016-12-16 US US15/381,562 patent/US20170121295A1/en not_active Abandoned
-
2018
- 2018-06-08 CY CY20181100603T patent/CY1120342T1/el unknown